9 June 2023
England–(Oxford Nanopore Technologies plc) The new platform is designed to enable the end-to-end analysis and clinical reporting of nanopore sequencing, empowering clinical labs, researchers and other users with an advanced, “one-click” solution.
Oxford Nanopore Technologies plc (Oxford Nanopore), the company delivering a new generation of nanopore-based molecular sensing technology, and Geneyx, an AI platform for human genetic analysis and interpretation, are aiming to team up to develop the first scalable software solution for the end-to-end analysis and clinical reporting of nanopore sequencing data. The advanced platform will seamlessly empower clinical centers, including hospitals, genetic labs, and researchers, with human whole-genomes, sequencing data and analysis.
The new software platform, which is anticipated to be commercially available following the completion of a pilot phase, is intended to advance the future clinical use of nanopore sequencing and will be designed to load, visualize and annotate nanopore sequencing data. Once available, it will be of immediate use in newborn screening and the research and characterization of rare and undiagnosed diseases, providing a “one-click” analysis of whole human sequencing data, including actionable genetic variants.
The collaboration will combine Geneyx’s data analysis capabilities with Oxford Nanopore’s human-variation workflow and secure data transfer. The platform will seamlessly integrate with EPI2ME™, Oxford Nanopore’s data analysis solution, which will perform the secondary sequence analysis. The results will then be pushed to the Geneyx cloud and on-site capability, where precise annotation and classification of the variants will be performed, providing a further layer of simplified bioinformatics designed for future clinical use.
The partnership will kick off with pilot projects to evaluate this software solution within third-party sites. The Geneyx solution is currently used by 4,000 active users in 36 countries worldwide.
Gordon Sanghera, CEO of Oxford Nanopore Technologies, commented: “We are excited to collaborate with Geneyx to develop an end-to-end analysis tool for the clinical reporting of nanopore sequencing data.“
David Yizhar, CEO, Geneyx commented:“This will enable us to deliver robust and accurate genetic insights to healthcare providers, including a comprehensive genomic solution for Long-Read whole genome sequencing analysis.“
“We are excited to collaborate with Geneyx to develop an end-to-end analysis tool for the clinical reporting of nanopore sequencing data. Through this seamless integration, customers will benefit from the combined power of nanopore sequencing with Geneyx’s AI-powered analysis for added layers of insight to support critical workflows such as newborn screening and research into rare diseases.”
“We are honoured to partner with Digi7 and Mediclinic in the Middle East and enable Geneyx to showcase its capabilities to a highly respected healthcare provider such as Mediclinic and gain valuable feedback to enhance our platform further. Additionally, working with Mediclinic Middle East helps to establish Geneyx as a trusted partner in the region’s overall healthcare market.” said David Yizhar, CEO Geneyx.
About Oxford Nanopore Technologies
Oxford Nanopore Technologies’ goal is to bring the widest benefits to society by enabling the analysis of anything by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 120 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes. www.nanoporetech.com
